Guardian Pharmacy Services Future Growth
Future criteria checks 3/6
Guardian Pharmacy Services is forecast to grow earnings and revenue by 34.3% and 7.6% per annum respectively while EPS is expected to grow by 1.8% per annum.
Key information
34.3%
Earnings growth rate
1.8%
EPS growth rate
Consumer Retailing earnings growth | 12.3% |
Revenue growth rate | 7.6% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 21 Oct 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,351 | 57 | 58 | 79 | 3 |
12/31/2025 | 1,318 | 50 | 52 | 72 | 3 |
12/31/2024 | 1,191 | 45 | 43 | 57 | 3 |
6/30/2024 | 1,119 | 14 | 53 | 67 | N/A |
3/31/2024 | 1,085 | 29 | 58 | 72 | N/A |
12/31/2023 | 1,046 | 24 | 56 | 71 | N/A |
9/30/2023 | 1,011 | 35 | 51 | 66 | N/A |
6/30/2023 | 976 | 47 | 45 | 62 | N/A |
3/31/2023 | 947 | 19 | 38 | 55 | N/A |
12/31/2022 | 909 | 35 | 32 | 49 | N/A |
9/30/2022 | 882 | 19 | 39 | 53 | N/A |
3/31/2022 | 822 | 34 | 49 | 60 | N/A |
12/31/2021 | 792 | 16 | 49 | 58 | N/A |
9/30/2021 | 771 | 31 | 48 | 57 | N/A |
3/31/2021 | 732 | 21 | 46 | 54 | N/A |
12/31/2020 | 736 | 20 | 44 | 53 | N/A |
9/30/2020 | 730 | 16 | 44 | 55 | N/A |
12/31/2019 | 698 | 22 | 42 | 56 | N/A |
9/30/2019 | 677 | 17 | 37 | 50 | N/A |
12/31/2018 | 600 | 15 | 34 | 44 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GRDN's forecast earnings growth (34.3% per year) is above the savings rate (2.5%).
Earnings vs Market: GRDN's earnings (34.3% per year) are forecast to grow faster than the US market (15.1% per year).
High Growth Earnings: GRDN's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: GRDN's revenue (7.6% per year) is forecast to grow slower than the US market (8.9% per year).
High Growth Revenue: GRDN's revenue (7.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GRDN's Return on Equity is forecast to be high in 3 years time